These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 15810575)
21. Is there HOPE for ALLHat: similarities and differences. Sica DA Expert Rev Cardiovasc Ther; 2003 May; 1(1):1-2. PubMed ID: 15030291 [No Abstract] [Full Text] [Related]
22. [Lifestyle intervention for the prevention of cardiovascular disease]. Fokkema MR; Muskiet FA; van Doormaal JJ Ned Tijdschr Geneeskd; 2005 Nov; 149(47):2607-12. PubMed ID: 16355572 [TBL] [Abstract][Full Text] [Related]
23. Reducing the lifetime cardiovascular risk of New Zealanders. Stewart RA; White HD N Z Med J; 2007 Sep; 120(1261):U2708. PubMed ID: 17853930 [No Abstract] [Full Text] [Related]
24. [Approaches to creating a national program for the prevention of cardiovascular and other noninfectious diseases in Finland]. Puska P; Nissinen A; Tuomilehto J; Lahti T; Pietinen P Ter Arkh; 1985; 57(11):48-51. PubMed ID: 4082023 [No Abstract] [Full Text] [Related]
26. Hope for the future: early recognition of increased cardiovascular risk in children and how to deal with it. Masi S; Charakida M; Wang G; O'Neill F; Taddei S; Deanfield J Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16 Suppl 2():S61-4. PubMed ID: 19675441 [No Abstract] [Full Text] [Related]
28. Use of pharmacologic agents for treatment of diabetes mellitus, dyslipidemia, and hypertension in children and adolescents. Daniels SR Arch Pediatr Adolesc Med; 2009 Apr; 163(4):389-91. PubMed ID: 19349572 [No Abstract] [Full Text] [Related]
29. Community control of chronic diseases: a review of cardiovascular programmes. Nissinen A; Puska P WHO Reg Publ Eur Ser; 1991; 37():393-420. PubMed ID: 1817546 [No Abstract] [Full Text] [Related]
31. [The epidemiological situation regarding cardiovascular diseases in the Lodz voivodship as a justification for prevention programmes]. Maniecka-Bryła I; Bryła M; Stelmach W Ann Acad Med Stetin; 2005; 51 Suppl 1():97-103. PubMed ID: 16602434 [TBL] [Abstract][Full Text] [Related]
32. Impact of recent trial results on cardiovascular risk management (Hatter Institute Cardiac Horizons series). Cardiovasc J Afr; 2008; 19(6):328-31. PubMed ID: 19104733 [No Abstract] [Full Text] [Related]
33. The cardiovascular prevention and lifestyle quiz for cardiologists. De Sutter J; Conraads VM Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16 Suppl 2():S8-10. PubMed ID: 19675443 [No Abstract] [Full Text] [Related]
34. [Prevention of cardiovascular diseases and patient compliance: limiting factors and proposals]. Ducobu J Rev Med Brux; 2000 Oct; 21(5):429-33. PubMed ID: 11109894 [TBL] [Abstract][Full Text] [Related]
35. National Coordinators: an active network dedicated to CVD prevention. Squarta S Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16 Suppl 2():S55-7. PubMed ID: 19675439 [No Abstract] [Full Text] [Related]
36. [Lipid therapy in risk patients. Do we concentrate too much on LDL cholesterol?]. März W MMW Fortschr Med; 2005 Apr; 147(14):14. PubMed ID: 15887675 [No Abstract] [Full Text] [Related]
37. Women and cardiovascular disease. Winterfeld A; Kent H NCSL Legisbrief; 2005; 13(19):1-2. PubMed ID: 15830440 [No Abstract] [Full Text] [Related]
39. New approaches in the intensive management of cardiovascular risk in the metabolic syndrome. Rosenson RS Curr Probl Cardiol; 2005 May; 30(5):241-79. PubMed ID: 15829899 [TBL] [Abstract][Full Text] [Related]